Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
MUPIROCIN
GLAXOSMITHKLINE PTE LTD
R01AX06
2% w/w
OINTMENT
MUPIROCIN 2% w/w
NASAL
Prescription Only
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations)
ACTIVE
1990-09-17
BACTROBAN NASAL MUPIROCIN CALCIUM AS FREE ACID QUALITATIVE AND QUANTITATIVE COMPOSITION Mupirocin calcium equivalent to 2% w/w mupirocin free acid in a white soft paraffin based ointment. PHARMACEUTICAL FORM Nasal ointment. CLINICAL PARTICULARS INDICATIONS Elimination of nasal carriage of staphylococci, including methicillin-resistant _Staphylococcus aureus_ (MRSA). For the treatment of bacterial skin infections _BACTROBAN_ ointment should be used. See package leaflet for this _BACTROBAN_ formulation or contact the manufacturer for details. DOSAGE AND ADMINISTRATION POPULATIONS _Adults and Children:_ _BACTROBAN_ nasal ointment should be applied to the anterior nostrils 2 to 3 times a day, as follows: A small amount of ointment, about the size of a match head is squeezed on the little finger or a cotton-tipped applicator, if available. The ointment is applied to the inside of one nostril. This is repeated for the other nostril. The nostrils are closed by pressing the sides of the nose together. This spreads the ointment throughout the nostrils. Nasal carriage should normally clear within 3 to 5 days of commencing treatment. Dosage should not exceed 10 days. Do not mix with other preparations as there is a risk of dilution, resulting in a reduction in the antibacterial activity and potential loss of stability of the mupirocin in the ointment. CONTRAINDICATIONS _BACTROBAN_ nasal ointment should not be given to patients with a history of hypersensitivity to mupirocin or any of the constituents of the preparations. WARNINGS AND PRECAUTIONS In the rare event of a possible sensitisation reaction or severe local irritation occurring with the use of the product, treatment should be discontinued, the product should be wiped off and appropriate alternative therapy for the infection instituted. As with other antibacterial products, prolonged use may result in overgrowth of non- susceptible organisms. Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening Read the complete document
BACTROBAN NASAL MUPIROCIN CALCIUM AS FREE ACID QUALITATIVE AND QUANTITATIVE COMPOSITION Mupirocin calcium equivalent to 2% w/w mupirocin free acid in a white soft paraffin based ointment. PHARMACEUTICAL FORM Nasal ointment. CLINICAL PARTICULARS INDICATIONS Elimination of nasal carriage of staphylococci, including methicillin-resistant _Staphylococcus aureus_ (MRSA). For the treatment of bacterial skin infections _BACTROBAN_ ointment should be used. See package leaflet for this _BACTROBAN_ formulation or contact the manufacturer for details. DOSAGE AND ADMINISTRATION POPULATIONS _Adults and Children:_ _BACTROBAN_ nasal ointment should be applied to the anterior nostrils 2 to 3 times a day, as follows: A small amount of ointment, about the size of a match head is squeezed on the little finger or a cotton-tipped applicator, if available. The ointment is applied to the inside of one nostril. This is repeated for the other nostril. The nostrils are closed by pressing the sides of the nose together. This spreads the ointment throughout the nostrils. Nasal carriage should normally clear within 3 to 5 days of commencing treatment. Dosage should not exceed 10 days. Do not mix with other preparations as there is a risk of dilution, resulting in a reduction in the antibacterial activity and potential loss of stability of the mupirocin in the ointment. CONTRAINDICATIONS _BACTROBAN_ nasal ointment should not be given to patients with a history of hypersensitivity to mupirocin or any of the constituents of the preparations. WARNINGS AND PRECAUTIONS In the rare event of a possible sensitisation reaction or severe local irritation occurring with the use of the product, treatment should be discontinued, the product should be wiped off and appropriate alternative therapy for the infection instituted. As with other antibacterial products, prolonged use may result in overgrowth of non- susceptible organisms. Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening Read the complete document